Hippocratic AI — Funding & Company Data
Financial overview and investor data for Hippocratic AI.
Founded
2023
Stage
Series c
Total Raised
$404M
HQ
Palo Alto, California
Team
51-200
Model
sales-led
Analyst Take
Hippocratic AI exhibits a hyper-growth trajectory, progressing from a large seed round to a Series C in approximately two and a half years. The velocity and size of its funding rounds are exceptional, underscoring the massive market opportunity and the capital-intensive nature of building a safety-focused, proprietary large language model for the heavily regulated healthcare industry. The investor syndicate is a blend of top-tier venture capital (a16z, General Catalyst, Kleiner Perkins) and strategic corporate capital (Nvidia, Google's CapitalG, and multiple health systems). [3, 7] This combination provides not only immense financial resources but also deep technical and industry validation. This strong financial backing gives Hippocratic AI a significant competitive moat, allowing it to fund the extensive safety testing, long sales cycles, and deep integrations required to win enterprise healthcare clients. For potential customers, this financial strength translates into a stable, well-resourced partner capable of long-term support and innovation.
Stability
The company is highly stable and well-capitalized. The recent $126 million Series C funding in November 2025 provides a substantial runway, ensuring the company will likely be a going concern for the next 3-5 years at a minimum. [3, 5, 15]
Growth
Hippocratic AI is in a state of hyper-growth. The rapid succession of funding rounds, a valuation of $3.5 billion, and partnerships with over 50 health systems, payers, and pharma clients demonstrate aggressive market penetration and strong product adoption. [3, 15]
For Buyers
For a potential buyer, the company's financial profile significantly de-risks a long-term commitment. Hippocratic AI is a well-funded market leader backed by the best in the industry, making the risk of service disruption due to financial failure extremely low.
Funding Timeline
Investors: Avenir Growth, CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, Universal Health Services, Cincinnati Children's Hospital Medical Center, WellSpan Health, John Doerr, Rick Klausner
Valuation: $3.5B
Investors: Kleiner Perkins, General Catalyst, Andreessen Horowitz, Nvidia, Premji Invest, SV Angel, Universal Health Services, WellSpan Health
Valuation: $1.64B
Investors: Premji Invest, General Catalyst, SV Angel, Memorial Hermann Health System, Andreessen Horowitz, Cincinnati Children's, WellSpan Health, Universal Health Services, NVentures, Greycroft, Lee Shapiro
Valuation: $500M
Notable Investors
Sources
- Hippocratic AI banks $141M series B, hits 'unicorn' status as it rolls out AI agent app store (fiercehealthcare.com)
- Hippocratic AI Raises $53 Million Series A at a $500 Million Valuation | UHS (uhsinc.com)
- Hippocratic AI Announces Series C Funding $126 Million (prnewswire.com)
- Hippocratic AI banks $53M backed by General Catalyst, a16z, Memorial Hermann, UHS and other health systems (fiercehealthcare.com)
- Hippocratic AI Receives Investment From NVentures to Build Generative AI Healthcare Agents (businesswire.com)
- Nvidia's venture arm backs $17M investment in Hippocratic AI to build out generative AI healthcare agents (fiercehealthcare.com)
- Top 6 health IT deals of Q2, per PitchBook (beckershospitalreview.com)
- Hippocratic AI's valuation soars to $3.5B after raising $126M in new funding (siliconangle.com)
- Hippocratic AI Company Profile: Valuation, Funding & Investors | PitchBook (pitchbook.com)
- Our Investment in Hippocratic AI - General Catalyst (generalcatalyst.com)